Analyst Ratings for Arcutis Biotherapeutics Inc. (ARQT)
ARQT Rating Summary
ARQT Price Target Summary
- Highest: $48.00 (Cantor Fitzgerald)
- Lowest: $33.00 (Goldman Sachs)
- Average: $37.44
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$37.44 (+29.9%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 84%
Avg. $ Target:
$37.44 (+29.9%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 84%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/15/2026 | Cantor Fitzgerald | Steve Seedhouse | New Coverage | Overweight (N/A) |
48.00 (N/A) |
26.41 (28.82) |
9.13% | Details |
| 7/25/2025 | Goldman Sachs » Updated 2/27/2026 |
Richard Law | New Coverage | Neutral (N/A) |
33.00 (29.00) |
14.91 (28.82) |
93.29% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
